Two Sigma Investments, LP Tricida, Inc. Transaction History

Two Sigma Investments, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $12.49 $88,566 - $7.9 Million	632,618 Added 148.17%	1,059,582 $158,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $649,866 - $1.04 Million	76,365 Added 21.78%	426,964 $4.48 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $37,566 - $60,897	5,139 Added 1.49%	350,599 $3.39 Million
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $161,185 - $233,115	-21,930 Reduced 5.97%	345,460 $2.84 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $968,166 - $2.21 Million	231,066 Added 169.5%	367,390 $3.51 Million

Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $967,939 - $1.26 Million	-271,893 Reduced 66.61%	136,324 $633,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $1.31 Million - $1.79 Million	-330,732 Reduced 44.76%	408,217 $1.76 Million
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $2.05 Million - $3.54 Million	453,342 Added 158.73%	738,949 $3.91 Million
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $505,381 - $1.09 Million	115,648 Added 68.04%	285,607 $2.01 Million
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $85,788 - $269,892	-10,022 Reduced 5.57%	169,959 $1.54 Million
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $1.87 Million - $2.77 Million	87,952 Added 95.57%	179,981 $4.95 Million
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $893,431 - $1.84 Million	48,477 Added 111.31%	92,029 $2.03 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $178,014 - $262,871	-6,014 Reduced 12.13%	43,552 $1.64 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $1.48 Million - $2.09 Million	49,566 New	49,566 $1.53 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.